{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:21:32Z","timestamp":1788398492650,"version":"build-2803163510"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.prp.2023.154702","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:10:10Z","timestamp":1689811810000},"page":"154702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The impact of microRNAs on the resistance of breast cancer subtypes to chemotherapy"],"prefix":"10.1016","volume":"249","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7698-2264","authenticated-orcid":false,"given":"Amir","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Bakhshaei Shahrebabaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Fouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Mansoori Derakhshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.prp.2023.154702_bib1","first-page":"524","article-title":"Breast cancer statistics","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.prp.2023.154702_bib2","first-page":"1427","article-title":"Etiology of breast cancer","author":"Singh","year":"2023","journal-title":"J. Pharm. Negat. Results"},{"issue":"6","key":"10.1016\/j.prp.2023.154702_bib3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/PPO.0b013e31823e5387","article-title":"The genetics of cancer risk","volume":"17","author":"Pomerantz","year":"2011","journal-title":"Cancer J. (Sudbury, Mass)"},{"issue":"1","key":"10.1016\/j.prp.2023.154702_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jbi\/wbaa110","article-title":"Molecular subtypes of breast cancer: a review for breast radiologists","volume":"3","author":"Johnson","year":"2021","journal-title":"J. Breast Imaging"},{"key":"10.1016\/j.prp.2023.154702_bib5","doi-asserted-by":"crossref","first-page":"15023","DOI":"10.1038\/npjbcancer.2015.23","article-title":"PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)","volume":"2","author":"Liu","year":"2016","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.prp.2023.154702_bib6","unstructured":"Orrantia-Borunda E., Anchondo-Nu\u00f1ez P., Acu\u00f1a-Aguilar L.E., G\u00f3mez-Valles F.O., Ram\u00edrez-Valdespino C.A. Subtypes of Breast Cancer. In: Mayrovitz HN, editor. Breast Cancer. Brisbane (AU): Exon Publications."},{"key":"10.1016\/j.prp.2023.154702_bib7","unstructured":"Copyright: The Authors, The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced, 2022."},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1634\/theoncologist.2017-0535","article-title":"Luminal a breast cancer and molecular assays: a review","volume":"23","author":"Gao","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2023.154702_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-biochem-060308-103103","article-title":"Regulation of mRNA translation and stability by microRNAs","volume":"79","author":"Fabian","year":"2010","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.prp.2023.154702_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1672-0229(08)60044-3","article-title":"A brief review on the mechanisms of miRNA regulation","volume":"7","author":"Cai","year":"2009","journal-title":"Genom. Proteom. Bioinforma."},{"issue":"21","key":"10.1016\/j.prp.2023.154702_bib11","article-title":"Role of microRNAs in chemoresistance","volume":"3","author":"Magee","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"7","key":"10.1016\/j.prp.2023.154702_bib12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ddr.21275","article-title":"The role of microRNAs in the chemoresistance of breast cancer","volume":"76","author":"Wang","year":"2015","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.prp.2023.154702_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118255","article-title":"MicroRNAs and colorectal cancer chemoresistance: new solution for old problem","volume":"259","author":"Vaghari-Tabari","year":"2020","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.prp.2023.154702_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/dna.2018.4529","article-title":"miR-21-5p suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting FASLG","volume":"38","author":"Chen","year":"2019","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.prp.2023.154702_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117162","article-title":"MiR-21 modulates the polarization of macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer","volume":"242","author":"An","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.prp.2023.154702_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00280-019-03867-6","article-title":"A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer","volume":"84","author":"Jin","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.prp.2023.154702_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10555-021-09973-3","article-title":"The comprehensive landscape of miR-34a in cancer research","volume":"40","author":"Li","year":"2021","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.prp.2023.154702_bib18","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.12659\/MSM.894475","article-title":"Influence of MiR-451 on drug resistances of paclitaxel-resistant breast cancer cell line","volume":"21","author":"Gu","year":"2015","journal-title":"Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res."},{"issue":"2","key":"10.1016\/j.prp.2023.154702_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13148-011-0040-8","article-title":"MicroRNA-mediated drug resistance in breast cancer","volume":"2","author":"Kutanzi","year":"2011","journal-title":"Clin. Epigenetics"},{"issue":"4","key":"10.1016\/j.prp.2023.154702_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers13040713","article-title":"Epigenetic alterations in triple-negative breast cancer\u2014the critical role of extracellular matrix","volume":"13","author":"Zolota","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154702_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.607689","article-title":"Nanoapproaches to modifying epigenetics of epithelial mesenchymal transition for treatment of pulmonary fibrosis","volume":"11","author":"Skibba","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2023.154702_bib22","first-page":"20","article-title":"p63 at the crossroads between stemness and metastasis in breast cancer","author":"Gatti","year":"2019","journal-title":"Int. J. Mol. Sci. [Internet]"},{"issue":"42","key":"10.1016\/j.prp.2023.154702_bib23","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1038\/onc.2014.475","article-title":"The origin of breast tumor heterogeneity","volume":"34","author":"Skibinski","year":"2015","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.prp.2023.154702_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000509025","article-title":"Histology of luminal breast cancer","volume":"15","author":"Erber","year":"2020","journal-title":"Breast Care"},{"issue":"3","key":"10.1016\/j.prp.2023.154702_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3679","article-title":"Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes","volume":"16","author":"Maisonneuve","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.prp.2023.154702_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-12-212","article-title":"The efficacy of molecular subtyping in predicting postoperative recurrence in breast-conserving therapy: a 15-study meta-analysis","volume":"12","author":"Chen","year":"2014","journal-title":"World J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2023.154702_bib27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4048\/jbc.2016.19.3.252","article-title":"BCL2 as a subtype-specific prognostic marker for breast cancer","volume":"19","author":"Eom","year":"2016","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.prp.2023.154702_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-0500-5-376","article-title":"Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype","volume":"5","author":"Yanagawa","year":"2012","journal-title":"BMC Res. Notes"},{"issue":"3","key":"10.1016\/j.prp.2023.154702_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/diseases5030016","article-title":"Epigenetic mechanisms of tamoxifen resistance in luminal breast cancer","volume":"5","author":"Abdel-Hafiz","year":"2017","journal-title":"Diseases"},{"key":"10.1016\/j.prp.2023.154702_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10549-014-3127-z","article-title":"Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome","volume":"148","author":"Baglia","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.prp.2023.154702_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/1535-7163.MCT-15-0548-T","article-title":"EGFR is regulated by TFAP2C in luminal breast cancer and is a target for vandetanibTFAP2C regulates breast cancer through EGFR","volume":"15","author":"De Andrade","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.prp.2023.154702_bib32","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10087","key":"10.1016\/j.prp.2023.154702_bib33","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.prp.2023.154702_bib34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.breast.2013.11.011","article-title":"Treatment of HER2-positive breast cancer","volume":"23","author":"Figueroa-Magalh\u00e3es","year":"2014","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.prp.2023.154702_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102569","article-title":"Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature)","volume":"14","author":"Smolarz","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"Suppl 6","key":"10.1016\/j.prp.2023.154702_bib36","doi-asserted-by":"crossref","first-page":"vi46","DOI":"10.1093\/annonc\/mds195","article-title":"Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents","volume":"23","author":"Andr\u00e9","year":"2012","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2023.154702_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.18433\/jpps30684","article-title":"The interaction of PI3K inhibition with homologous recombination repair in triple negative breast cancer cells","volume":"22","author":"Guney Eskiler","year":"2019","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.prp.2023.154702_bib38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: a review","volume":"169","author":"Costa","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2023.154702_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-015-3293-7","article-title":"Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer","volume":"150","author":"Wong-Brown","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.prp.2023.154702_bib40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41698-022-00303-6","article-title":"Impact of TP53 mutations in triple negative breast cancer","volume":"6","author":"Mitri","year":"2022","journal-title":"NPJ Precis. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2023.154702_bib41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.prp.2023.154702_bib42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib43","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3892\/or_00000963","article-title":"Chemotherapy for breast cancer","volume":"24","author":"Hassan","year":"2010","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.prp.2023.154702_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","article-title":"Progress in adjuvant chemotherapy for breast cancer: an overview","volume":"13","author":"Anampa","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.prp.2023.154702_bib45","first-page":"1","article-title":"MiRNA biogenesis and regulation of diseases: an overview","author":"Vishnoi","year":"2017","journal-title":"Micro Profil.: Methods Protoc."},{"issue":"7","key":"10.1016\/j.prp.2023.154702_bib46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.tibs.2010.03.009","article-title":"Making risc","volume":"35","author":"Kawamata","year":"2010","journal-title":"Trends Biochem. Sci."},{"issue":"35","key":"10.1016\/j.prp.2023.154702_bib47","doi-asserted-by":"crossref","first-page":"59950","DOI":"10.18632\/oncotarget.19048","article-title":"The molecular mechanisms of chemoresistance in cancers","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154702_bib48","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/j.csbj.2022.08.031","article-title":"Single-cell transcriptomics of neuroblastoma identifies chemoresistance-associated genes and pathways","volume":"20","author":"Avitabile","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"9","key":"10.1016\/j.prp.2023.154702_bib49","first-page":"12","article-title":"Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies","author":"Gupta","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.prp.2023.154702_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247837","article-title":"The overexpression of DNA repair genes in invasive ductal and lobular breast carcinomas: insights on individual variations and precision medicine","volume":"16","author":"Mohamed","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib51","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.3390\/curroncol29050236","article-title":"PIK3CA mutation as potential poor prognostic marker in asian female breast cancer patients who received adjuvant chemotherapy","volume":"29","author":"Cho","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.prp.2023.154702_bib52","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.2147\/CMAR.S172722","article-title":"Identification of chemoresistance-associated miRNAs in breast cancer","volume":"10","author":"Lou","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib53","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/onc.2011.260","article-title":"miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222","volume":"31","author":"Acunzo","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2023.154702_bib54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-017-0222-6","article-title":"The effect of miR-200c inhibition on chemosensitivity (5-FluoroUracil) in colorectal cancer","volume":"24","author":"Heydari","year":"2018","journal-title":"Pathol. Oncol. Res."},{"issue":"21","key":"10.1016\/j.prp.2023.154702_bib55","first-page":"332","article-title":"Role of microRNAs in chemoresistance","volume":"3","author":"Magee","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.prp.2023.154702_bib56","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/jcmm.16110","article-title":"miR\u201015a\u20105p and miR\u201021\u20135p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2","volume":"25","author":"Vandewalle","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.prp.2023.154702_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175233","article-title":"Downregulation of miR-21 as a promising strategy to overcome drug resistance in cancer","author":"Akhtarkhavari","year":"2022","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.prp.2023.154702_bib58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/nat.2020.0914","article-title":"MiR-21: a key small molecule with great effects in combination cancer therapy","volume":"31","author":"Arghiani","year":"2021","journal-title":"Nucleic Acid. Ther."},{"issue":"12","key":"10.1016\/j.prp.2023.154702_bib59","doi-asserted-by":"crossref","first-page":"e105-e","DOI":"10.1038\/cddis.2010.85","article-title":"Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells","volume":"1","author":"Bhatnagar","year":"2010","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.prp.2023.154702_bib60","doi-asserted-by":"crossref","first-page":"9360","DOI":"10.3390\/ijms24119360","article-title":"The mechanism of DNA methylation and miRNA in breast cancer","volume":"24","author":"Ma","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154702_bib61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.critrevonc.2017.01.020","article-title":"Epigenetic control of gene expression: potential implications for cancer treatment","volume":"111","author":"Perri","year":"2017","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"10","key":"10.1016\/j.prp.2023.154702_bib62","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.tcb.2015.07.002","article-title":"Control of chromatin structure by long noncoding RNA","volume":"25","author":"B\u00f6hmdorfer","year":"2015","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.prp.2023.154702_bib63","article-title":"microRNA-221 and tamoxifen resistance in luminal-subtype breast cancer patients: a case-control study","volume":"73","author":"Amiruddin","year":"2022","journal-title":"Ann. Med Surg. (Lond.)"},{"issue":"44","key":"10.1016\/j.prp.2023.154702_bib64","doi-asserted-by":"crossref","first-page":"29897","DOI":"10.1074\/jbc.M804612200","article-title":"MicroRNA-221\/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1","volume":"283","author":"Miller","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.prp.2023.154702_bib65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4048\/jbc.2017.20.1.35","article-title":"MicroRNA-222 expression as a predictive marker for tumor progression in hormone receptor-positive breast cancer","volume":"20","author":"Han","year":"2017","journal-title":"J. Breast Cancer"},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib66","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.18632\/oncotarget.6790","article-title":"MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216400","article-title":"MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines","volume":"14","author":"Uhr","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000937","article-title":"MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer","volume":"5","author":"Petrelli","year":"2020","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.prp.2023.154702_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104870","article-title":"Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.prp.2023.154702_bib70","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1056\/NEJM200101253440407","article-title":"Estrogen and the risk of breast cancer","volume":"344","author":"Clemons","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217181","article-title":"Norcantharidin regulates ER\u03b1 signaling and tamoxifen resistance via targeting miR-873\/CDK3 in breast cancer cells","volume":"14","author":"Zhang","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.prp.2023.154702_bib72","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41416-019-0395-8","article-title":"MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer","volume":"120","author":"Milevskiy","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2023.154702_bib73","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fgene.2018.00174","article-title":"Screen for MicroRNA and drug interactions in breast cancer cell lines points to miR-126 as a modulator of CDK4\/6 and PIK3CA Inhibitors","volume":"9","author":"Baldassari","year":"2018","journal-title":"Front. Genet."},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib74","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/0008-5472.CAN-19-1793","article-title":"Downregulation of miR-223 expression is an early event during mammary transformation and confers resistance to CDK4\/6 inhibitors in luminal breast cancer","volume":"80","author":"Citron","year":"2020","journal-title":"Cancer Res."},{"issue":"48","key":"10.1016\/j.prp.2023.154702_bib75","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1038\/onc.2016.151","article-title":"MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1","volume":"35","author":"Venturutti","year":"2016","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.prp.2023.154702_bib76","doi-asserted-by":"crossref","first-page":"941","DOI":"10.17219\/acem\/70745","article-title":"Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol","volume":"27","author":"Asghari","year":"2018","journal-title":"Adv. Clin. Exp. Med."},{"issue":"35","key":"10.1016\/j.prp.2023.154702_bib77","doi-asserted-by":"crossref","first-page":"37269","DOI":"10.18632\/oncotarget.5495","article-title":"MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.prp.2023.154702_bib78","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.prp.2023.154702_bib79","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1038\/s41598-023-32757-4","article-title":"Identification and panoramic analysis of drug response-related genes in triple negative breast cancer using as an example NVP-BEZ235","volume":"13","author":"Feng","year":"2023","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.prp.2023.154702_bib80","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2014.57.0085","article-title":"Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1\/2 mutation\u2013associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105","volume":"33","author":"Telli","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2023.154702_bib81","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.gendis.2015.07.003","article-title":"Promising molecular mechanisms responsible for gemcitabine resistance in cancer","volume":"2","author":"Jia","year":"2015","journal-title":"Genes Dis."},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib82","first-page":"2276","article-title":"miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells","volume":"9","author":"Li","year":"2017","journal-title":"Am. J. Transl. Res."},{"issue":"1","key":"10.1016\/j.prp.2023.154702_bib83","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12935-022-02681-0","article-title":"Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer","volume":"22","author":"Xi","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"8","key":"10.1016\/j.prp.2023.154702_bib84","article-title":"(18)F-FDG PET\/CT for monitoring the response of breast cancer to miR-143-based therapeutics by targeting tumor glycolysis","volume":"5","author":"Miao","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.prp.2023.154702_bib85","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/1471-2407-13-537","article-title":"Wnt signaling in triple negative breast cancer is associated with metastasis","volume":"13","author":"Dey","year":"2013","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.prp.2023.154702_bib86","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1158\/1538-7445.AM2019-3821","article-title":"Abstract 3821: taxane resistance in breast cancer controlled by the APC tumor suppressor","volume":"79","author":"Astarita","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2023.154702_bib87","doi-asserted-by":"crossref","DOI":"10.1007\/s10528-023-10331-x","article-title":"Evaluation of Circ_0000977-mediated regulatory network in breast cancer: a potential discriminative biomarker for triple-negative tumors","author":"Darbeheshti","year":"2023","journal-title":"Biochem. Genet."},{"issue":"3","key":"10.1016\/j.prp.2023.154702_bib88","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.31557\/APJCP.2022.23.3.1053","article-title":"Down regulated expression levels of miR-27b and miR-451a as a potential biomarker for triple negative breast cancer patients undergoing TAC chemotherapy","volume":"23","author":"Abdul Aziz","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.prp.2023.154702_bib89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2019.08.016","article-title":"MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1\/CSN5 in triple-negative breast cancer","volume":"465","author":"Wang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2023.154702_bib90","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.biopha.2018.07.076","article-title":"Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer","volume":"107","author":"Tang","year":"2018","journal-title":"Biomed. Pharm."},{"issue":"11","key":"10.1016\/j.prp.2023.154702_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112637","article-title":"Dual epigenetic regulation of ER\u03b136 expression in breast cancer cells","volume":"20","author":"Thiebaut","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154702_bib92","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","article-title":"Extracellular matrix in the tumor microenvironment and its impact on cancer therapy","volume":"6","author":"Henke","year":"2019","journal-title":"Front Mol. Biosci."},{"issue":"1","key":"10.1016\/j.prp.2023.154702_bib93","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41467-020-16199-4","article-title":"Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer","volume":"11","author":"Saatci","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.prp.2023.154702_bib94","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-022-06569-5","article-title":"Targeting HIF1-alpha\/miR-326\/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer","volume":"193","author":"Assidicky","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2023.154702_bib95","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00280-006-0224-7","article-title":"Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1\u03b1 gene","volume":"58","author":"Song","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.prp.2023.154702_bib96","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10549-018-4925-5","article-title":"Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells","volume":"172","author":"Ozawa","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.prp.2023.154702_bib97","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10549-018-4847-2","article-title":"Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer","volume":"171","author":"Kabil","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"17","key":"10.1016\/j.prp.2023.154702_bib98","doi-asserted-by":"crossref","first-page":"28939","DOI":"10.18632\/oncotarget.15960","article-title":"Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation","volume":"8","author":"Drago-Ferrante","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.prp.2023.154702_bib99","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jsps.2021.04.007","article-title":"Improved delivery of miR-1296 loaded cationic nanoliposomes for effective suppression of triple negative breast cancer","volume":"29","author":"Albakr","year":"2021","journal-title":"Saudi Pharm. J."},{"issue":"21","key":"10.1016\/j.prp.2023.154702_bib100","doi-asserted-by":"crossref","first-page":"14868","DOI":"10.1074\/jbc.M114.552257","article-title":"The retinaldehyde reductase activity of DHRS3 is reciprocally activated by retinol dehydrogenase 10 to control retinoid homeostasis","volume":"289","author":"Adams","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.prp.2023.154702_bib101","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13046-021-01941-7","article-title":"Inhibition of retinoic acid receptor \u03b1 phosphorylation represses the progression of triple-negative breast cancer via transactivating miR-3074-5p to target DHRS3","volume":"40","author":"Lou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2023.154702_bib102","first-page":"13","article-title":"miR-21 plays a dual role in tumor formation and cytotoxic response in breast tumors","author":"Dan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.prp.2023.154702_bib103","first-page":"673","article-title":"Ursolic acid enhances cytotoxicity of doxorubicin-resistant triple-negative breast cancer cells via ZEB1-AS1\/miR-186-5p\/ABCC1 axis","volume":"37","author":"Lu","year":"2022","journal-title":"Cancer Biother Radiol."},{"key":"10.1016\/j.prp.2023.154702_bib104","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s12935-020-01547-7","article-title":"CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p\/CDCA3 axis","volume":"20","author":"Dou","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"24","key":"10.1016\/j.prp.2023.154702_bib105","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1158\/0008-5472.CAN-14-1140","article-title":"Targeting of miR34a\u2013NOTCH1 axis reduced breast cancer stemness and chemoresistance","volume":"74","author":"Park","year":"2014","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2023.154702_bib106","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.drup.2010.07.001","article-title":"Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance","volume":"13","author":"Wang","year":"2010","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.prp.2023.154702_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-021-00206-5","article-title":"MiRNA-mediated E.M.T. and CSCs in cancer chemoresistance","volume":"10","author":"Dong","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.prp.2023.154702_bib108","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/TCRM.S154226","article-title":"The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma","author":"Ren","year":"2018","journal-title":"Ther. Clin. Risk Manag."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823004028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823004028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T07:00:24Z","timestamp":1759734024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823004028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":108,"alternative-id":["S0344033823004028"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154702","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of microRNAs on the resistance of breast cancer subtypes to chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"154702"}}